Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALB | P02768 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833983 | 0.91 | AKR1C2 (0.42) | PLK1AKR1C2AKR1C1ALBRXFP1 | |
| SCHEMBL6830475 | 0.91 | ALB (0.46) | AKR1C2AKR1C1ALBRXFP1LMNA | |
| SCHEMBL6834068 | 0.89 | ALB (0.43) | AKR1C2AKR1C1ALBRXFP1LMNA | |
| SCHEMBL6814183 | 0.88 | MRGPRX4 (0.43) | ALBRXFP1LMNAMAPTTRPM4 | |
| SCHEMBL6833872 | 0.86 | KDM1A (0.43) | ALBRXFP1LMNAMAPTTRPM4 | |
| SCHEMBL6834587 | 0.86 | CYP1A2 (0.38) | ALBRXFP1LMNAMAPTALDH1A1 | |
| SCHEMBL6830121 | 0.85 | ALB (0.40) | AKR1C2AKR1C1ALBRXFP1LMNA | |
| SCHEMBL6833805 | 0.85 | ALK (0.39) | AKR1C2AKR1C1ALBRXFP1LMNA | |
| SCHEMBL6834267 | 0.85 | KDM1A (0.42) | ALBRXFP1LMNAMAPTTRPM4 | |
| SCHEMBL6833801 | 0.85 | ALK (0.39) | AKR1C2AKR1C1ALBRXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PLK1 4270/4885AKR1C2 2596/4885AKR1C1 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.